Trial
NCT01077154
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Amgen
Collaborators
Daiichi Sankyo
Condition
Breast Cancer
Intervention
Placebo
Why stopped
Terminated: Amgen decision following Primary Analysis. Not due to safety reason
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-09-28